Recent progress in the computational prediction of aqueous solubility and absorption

AAPS Journal

Volumn 8, Issue 1, 2006, Pages E27-E40

  Johnson, Stephen R ^a,c   Zheng, Weifan ^b  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

BCS; In silico; P glycoprotein; Permeability; Prediction; Solubility

Indexed keywords

BUPIVACAINE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PHENOTHIAZINE DERIVATIVE; WATER;

AQUEOUS SOLUTION; ARTIFICIAL NEURAL NETWORK; CHEMISTRY; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; HUMAN; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR WEIGHT; NONHUMAN; PREDICTION; PROTEIN TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; REVIEW; STATISTICAL MODEL; ABSORPTION; ANIMAL; BIOLOGICAL MODEL; BIOLOGY; INTESTINE ABSORPTION; METABOLISM; PHYSIOLOGY; PREDICTION AND FORECASTING; SOLUBILITY;

ABSORPTION; ANIMALS; COMPUTATIONAL BIOLOGY; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; SOLUBILITY; WATER;

EID: 33747183101     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080104     Document Type: Review

References (119)

1. Amidon GL, Lennernaes H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
2. Center for Drug Evaluation and Research. Guidance for Industry. Rockville, MD: CDER/FDA; 2000.
3. Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19:921-925.
4. Valko K. Measurements and predictions of physicochemical properties. High-Throughput ADMETox Estimation. 2002;1-24:A21-A25.
5. Lipinski C. Aqueous solubility in discovery, chemistry, and assay changes. Methods Principles Med Chem. 2003;18:215-231.
6. Lombardo F, Gifford E, Shalaeva MY. In silico ADME prediction: data, models, facts and myths. Mini Rev Med Chem. 2003;3:861-875.
7. Delaney JS. Predicting aqueous solubility from structure. Drug Discov Today. 2005;10:289-295.
8. Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002;54:355-366.
9. Eros D, Keri G, Kovesdi I, Szantai-Kis C, Meszaros G, Orfi L. Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS, and ANN methods. Mini Rev Med Chem. 2004;4:167-177.
10. Taskinen J, Yliruusi J. Prediction of physicochemical properties based on neural network modelling. Adv Drug Deliv Rev. 2003;55:1163-1183.
11. McFarland JW, Du CM, Avdeef A. Factors influencing the water solubilities of crystalline drugs. Methods Principles Med Chem. 2003;18:232-242.
12. Stouch TR, Kenyon JR, Johnson SR, Chen X-Q, Doweyko A, Li Y. In silico ADME/Tox: why models fail. J Comput Aided Mol Des. 2003;17:83-92.
13. Bergstrom CA, Wassvik CM, Norinder U, Luthman Y, Artursson P. Global and local computational models for aqueous solubility prediction of drug-like molecules. J Chem Inf Comput Sci. 2004;44:1477-1488.
14. Cheng A Jr, Merz KM Jr. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. J Med Chem. 2003;46:3572-3580.
15. Bergstrom CA. In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin Pharmacol Toxicol. 2005;96:156-161.
16. Bergstrom CAS, Norinder U, Luthman K, Artursson P. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res. 2002;19:182-188.
17. Chen X-Q, Cho SJ, Li Y, Venkatesh S. Prediction of aqueous solubility of organic compounds using a quantitative structure-property relationship. J Pharm Sci. 2002;91:1838-1852.
18. Lobell M, Sivarajah V. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Divers. 2003;7:69-87.
19. Votano JR, Parham M, Hall LH, Kier LB, Hall LM. Prediction of aqueous solubility based on large datasets using several QSPR models utilizing topological structure representation. Chem Biodivers. 2004;1:1829-1841.
20. Hilal SH, Karickhoff SW, Carreira LA. Prediction of the solubility, activity coefficient and liquid/liquid partition coefficient of organic compounds. QSAR Combinator Sci. 2004;23:709-720.
21. Nohair M, Zakarya D. Prediction of solubility of aliphatic alcohols using the restricted components of autocorrelation method (RCAM). J Mol Model (Online). 2003;9:365-371.
22. Yan A, Gasteiger J. Prediction of aqueous solubility of organic compounds by topological descriptors. QSAR Combinator Sci. 2003;22:821-829.
23. Hou TJ, Xia K, Zhang W, Xu XJ. ADME evaluation in drug discovery, IV: prediction of aqueous solubility based on atom contribution approach. J Chem Inf Comput Sci. 2004;44:266-275.
24. Xia X, Maliski E, Cheetham J, Poppe L. Solubility prediction by recursive partitioning. Pharm Res. 2003;20:1634-1640.
25. Yan A, Gasteiger J. Prediction of aqueous solubility of organic compounds based on a 3D structure representation. J Chem Inf Comput Sci. 2003;43:429-434.
26. Yin C, Liu X, Guo W, Lin T, Wang X, Wang L. Prediction and application in QSPR of aqueous solubility of sulfur-containing aromatic esters using GA-based MLR with quantum descriptors. Water Res. 2002;36:2975-2982.
27. Klamt A, Eckert F, Hornig M, Beck ME, Burger T. Prediction of aqueous solubility of drugs and pesticides with COSMO-RS. J Comput Chem. 2002;23:275-281.
28. Bergstrom CA, Wassvik CM, Norinder U, Luthman K, Artursson P. Global and local computational models for aqueous solubility prediction of drug-like molecules. J Chem Inf Comput Sci. 2004;44:1477-1488.
29. Yan A, Gasteiger J, Krug M, Anzali S. Linear and nonlinear functions on modeling of aqueous solubility of organic compounds by two structure representation methods. J Comput Aided Mol Des. 2004;18:75-87.
30. Manallack DT, Tehan BG, Gancia E, et al. A consensus neural network-based technique for discriminating soluble and poorly soluble compounds. J Chem Inf Comput Sci. 2003;43:674-679.
31. Ma W, Zhang X, Luan F, et al. Support vector machine and the heuristic method to predict the solubility of hydrocarbons in electrolyte. J Phys Chem A. 2005;109:3485-3492.
32. Tetko IV, Bruneau P. Application of ALOGPS to predict 1-octanol/water distribution coefficients, logP, and logD, of AstraZeneca in-house database. J Pharm Sci. 2004;93:3103-3110.
33. Thompson JD, Cramer CJ, Truhlar DG. Predicting aqueous solubilities from aqueous free energies of solvation and experimental or calculated vapor pressures of pure substances. J Chem Phys. 2003;119:1661-1670.
34. Wegner JK, Zell A. Prediction of aqueous solubility and partition coefficient optimized by a genetic algorithm based descriptor selection method. J Chem Inf Comput Sci. 2003;43:1077-1084.
35. Engkvist O, Wrede P. High-throughput, in silico prediction of aqueous solubility based on one- and two-dimensional descriptors. J Chem Inf Comput Sci. 2002;42:1247-1249.
36. Raevsky OA, Raevskaja OE, Schaper K-J. Analysis of water solubility data on the basis of HYBOT descriptors, part 3: solubility of solid neutral chemicals and drugs. QSAR Combinator Sci. 2004;23:327-343.
37. Schaper K-J, Kunz B, Raevsky OA. Analysis of water solubility data on the basis of HYBOT descriptors, part 2: solubility of liquid chemicals and drugs. QSAR Combinator Sci. 2003; 22:943-958.
38. Huuskonen J, Salo M, Taskinen J. Aqueous solubility prediction of drugs based on molecular topology and neural network modeling. J Chem Inf Comput Sci. 1998;38:450-456.
39. Jorgensen WL, Duffy EM. Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett. 2000;10:1155-1158.
40. Tantishaiyakul V. Prediction of aqueous solubility of organic salts of diclofenac using PLS and molecular modeling. Int J Pharm. 2004;275:133-139.
41. Tantishaiyakul V. Prediction of the aqueous solubility of benzylamine salts using QSPR model. J Pharm Biomed Anal. 2005;37:411-415.
42. Parshad H, Frydenvang K, Liljefors T, Larsen CS. Correlation of aqueous solubility of salts of benzylamine with experimentally and theoretically derived parameters: a multivariate data analysis approach. Int J Pharm. 2002;237:193-207.
43. Ikeda H, Chiba K, Kanou A, Hirayama N. Prediction of solubility of drugs by conductor-like screening model for real solvents. Chem Pharm Bull (Tokyo). 2005;53:253-255.
44. Hendriksen BA, Felix MV, Bolger MB. The composite solubility versus pH profile and its role in intestinal absorption prediction. AAPS PharmSci. 2003;5:E4.
45. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46:75-87.
46. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50:S41-S67.
47. Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res. 2003;20:1917-1925.
48. Bergstrom CAS, Luthman K, Artursson P. Accuracy of calculated pH-dependent aqueous drug solubility. Eur J Pharm Sci. 2004;22:387-398.
49. Setschenow JZ. Uber Die Konstitution Der Salzlosungenauf Grund Ihres Verhaltens Zu Kohlensaure. Z Physik Chem. 1889;4:117-125.
50. Ni N, Yalkowsky SH. Prediction of Setschenow constants. Int J Pharm. 2003;254:167-172.
51. Li Y, Hu Q, Zhong C. Topological modeling of the Setschenow constant. Ind Eng Chem Res. 2004;43:4465-4468.
52. Gould PL. Salt selection for basic drugs. Int J Pharm. 1986;33:201-217.
53. Reid RC, Pransnitz JM, Poling BE. The Properties of Gases and Liquids. New York, NY: McGraw Hill; 1984.
54. Hribar B, Southall NT, Vlachy V, Dill KA. How ions affect the structure of water. J Am Chem Soc. 2002;124:12302-12311.
55. Abraham MH, Le J. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. J Pharm Sci. 1999;88:868-880.
56. Huang L-F, Tong W-Q. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev. 2004;56:321-334.
57. Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharm Sci. 2005;94:929-939.
58. Nielsen AB, Frydenvang K, Liljefors T, Buur A, Larsen C. Assessment of the combined approach of N-alkylation and salt formation to enhance aqueous solubility of tertiary amines using bupivacaine as a model drug. Eur J Pharm Sci. 2005;24:85-93.
59. Romero AJ, Rhodes CT. Stereochemical aspects of the molecular pharmaceutics of ibuprofen. J Pharm Pharmacol. 1993;45:258-262.
60. Sanghvi T, Jain N, Yang G, Yalkowsky SH. Estimation of aqueous solubility by the general solubility equation (GSE) the easy way. QSAR Combinator Sci. 2003;22:258-262.
61. Bergstrom CA, Norinder U, Luthman K, Artursson P. Molecular descriptors influencing melting point and their role in classification of solid drugs. J Chem Inf Comput Sci. 2003;43:1177-1185.
62. Jain A, Yang G, Yalkowsky SH. Estimation of melting points of organic compounds. Ind Eng Chem Res. 2004;43:7618-7621.
63. Johnson JLH, Yalkowsky SH. Two new parameters for predicting the entropy of melting: eccentricity (e) and spirality (m). Ind Eng Chem Res. 2005;44:7559-7566.
64. Karthikeyan M, Glen RC, Bender A. General melting point prediction based on a diverse compound data set and artificial neural networks. J Chem Inf Model. 2005;45:581-590.
65. Thomas E, Rubino J. Solubility, melting point and salting-out relationships in a group of secondary amine hydrochloride salts. Int J Pharm. 1996;130:179-185.
66. Katritzky AR, Jain R, Lomaka A, Petrukhin R, Maran U, Karelson M. Perspective on the relationship between melting points and chemical structure. Cryst Growth Des. 2001;1:261-265.
67. Raevsky OA, Schaper K-J, Seydel JK. H-bond contribution to octanol-water partition coefficients of polar compounds. Quant Struct-Activ Relat. 1995;14:433-436.
68. Raevsky OA. Hydrogen bond strength estimation by means of the HYBOT program package. In: van de Waterbeemd H, Testa B, Folkers G, eds. Computer-Assisted Lead Finding and Optimization. Basel, Switzerland: Verlag Helvetica Chimica Acta; 1997:369-378.
69. Raevsky OA, Grigor'ev VG. Quantitative description of lipophilicity of organic chemicals on the basis of polarizability and H-bond acceptor factors. Chem-Pharm Z (Rus). 1999;33:46-49.
70. Raevsky OA, Schaper KJ, van de Waterbeemd H, McFarland JW. Hydrogen bond contributions to properties and activities of chemicals and drugs. In: Gundertofte K, Jorgensen FS, eds. Molecular Modeling and Prediction of Bioactivity. New York, NY: Springer; 2000:221-227.
71. Ran Y, He Y, Yang G, Johnson JLH, Yalkowsky SH. Estimation of aqueous solubility of organic compounds by using the general solubility equation. Chemosphere. 2002;48:497-509.
72. Ouvrard C, Mitchell JBO. Can we predict lattice energy from molecular structure? Acta Crystallogr B. 2003;59:676-685.
73. Copley RCB, Deprez LS, Lewis TC, Price SL. Computational prediction and X-ray determination of the crystal structures of 3-oxauracil and 5-hydroxyuracil - an informal blind test. CrystEngComm. 2005;7:421-428.
74. Dey A, Kirchner MT, Vangala VR, Desiraju GF, Mondal R, Howard JAK. Crystal structure prediction of aminols: advantages of a supramolecular synthon approach with experimental structures. J Am Chem Soc. 2005;127:10545-10559.
75. Price SL. Quantifying intermolecular interactions and their use in computational crystal structure prediction. CrystEngComm. 2004;6:344-353.
76. Price SL. The computational prediction of pharmaceutical crystal structures and polymorphism. Adv Drug Deliv Rev. 2004;56:301-319.
77. Datta S, Grant DJ. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov. 2004;3:42-57.
78. Gavezzotti A. A molecular dynamics test of the different stability of crystal polymorphs under thermal strain. J Am Chem Soc. 2000;122:10724-10725.
79. Gavezzotti A. The chemistry of intermolecular bonding: organic crystals, their structures and transformations. Synlett. 2002;2002:0201-0214.
80. Gavezzotti A. Quantitative ranking of crystal packing modes by systematic calculations on potential energies and vibrational amplitudes of molecular dimers. J Chem Theory Computat. 2005;1:834-840.
81. Pajeva I, Wiese M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J Med Chem. 1998;41:1815-1826.
82. Pajeva IK, Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J Med Chem. 2002;45:5671-5686.
83. Ekins S, Kim RB, Leake BF, et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol. 2002;61:974-981.
84. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem. 2002;45:1737-1740.
85. Xue Y, Yap CW, Sun LZ, Cao ZW, Wang JF, Chen YZ. Prediction of P-glycoprotein substrates by a support vector machine approach. J Chem Inf Comput Sci. 2004;44:1497-1505.
86. Wang YH, Li Y, Yang SL, Yang L. An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. J Comput Aided Mol Des. 2005;19:137-147.
87. Wang YH, Li Y, Yang SL, Yang L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model. 2005;45:750-757.
88. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci. 2004;93:957-968.
89. Cianchetta G, Singleton RW, Zhang M, et al. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J Med Chem. 2005;48:2927-2935.
90. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem. 1998;251:252-261.
91. Ekins S, Kim RB, Leake BF, et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002;61:964-973.
92. Balimane PV, Chong S. Cell culture-based models for intestinal permeability: a critique. Drug Discov Today. 2005;10:335-343.
93. Bergstrom CA. In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin Pharmacol Toxicol. 2005;96:156-161.
94. Malkia A, Murtomaki L, Urtti A, Kontturi K. Drug permeation in biomembranes: in vitro and in silico prediction and influence of physicochemical properties. Eur J Pharm Sci. 2004;23:13-47.
95. Kulkarni A, Han Y, Hopfinger AJ. Predicting Caco-2 cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis. J Chem Inf Comput Sci. 2002;42:331-342.
96. Yamashita F, Wanchana S, Hashida M. Quantitative structure/property relationship analysis of Caco-2 permeability using a genetic algorithm-based partial least squares method. J Pharm Sci. 2002;91:2230-2239.
97. Yamashita F, Fujiwara S, Hashida M. The "latent membrane permeability" concept: QSPR analysis of inter/intralaboratory variable Caco-2 permeability. J Chem Inf Comput Sci. 2002;42:408-413.
98. Fujiwara S, Yamashita F, Hashida M. Prediction of Caco-2 cell permeability using a combination of MO-calculation and neural network. Int J Pharm. 2002;237:95-105.
99. Marrero Ponce Y, Cabrera Perez MA, Romero Zaldivar V, Gonzalez Diaz H, Torrens F. A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci. 2004;7:186-199.
100. Hou TJ, Zhang W, Xia K, Qiao XB, Xu XJ. ADME evaluation in drug discovery, V: correlation of Caco-2 permeation with simple molecular properties. J Chem Inf Comput Sci. 2004;44:1585-1600.
101. Fujikawa M, Ano R, Nakao K, Shimizu R, Akamatsu M. Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg Med Chem. 2005;13:4721-4732.
102. Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS. In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem. 2005;48:805-811.
103. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 1996;22:67-84.
104. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3-25.
105. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem. 2004;47:4022-4031.
106. Usansky HH, Sinko PJ. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a). J Pharmacol Exp Ther. 2005;314:391-399.
107. Obata K, Sugano K, Saitoh R, et al. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int J Pharm. 2005;293:183-192.
108. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615-2623.
109. Lu JJ, Crimin K, Goodwin JT, et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem. 2004;47:6104-6107.
110. Vieth M, Siegel MG, Higgs RE, et al. Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem. 2004;47:224-232.
111. Martin YC. A bioavailability score. J Med Chem. 2005;48:3164-3170.
112. Liu HX, Hu RJ, Zhang RS, et al. The prediction of human oral absorption for diffusion rate-limited drugs based on heuristic method and support vector machine. J Comput Aided Mol Des. 2005;19:33-46.
113. Bai JP, Utis A, Crippen G, et al. Use of classification regression tree in predicting oral absorption in humans. J Chem Inf Comput Sci. 2004;44:2061-2069.
114. Turner JV, Maddalena DJ, Agatonovic-Kustrin S. Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm Res. 2004;21:68-82.
115. Zmuidinavicius D, Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption. J Pharm Sci. 2003;92:621-633.
116. Klopman G, Stefan LR, Saiakhov RD. ADME evaluation, II: a computer model for the prediction of intestinal absorption in humans. Eur J Pharm Sci. 2002;17:253-263.
117. Yoshida F, Topliss JG. QSAR model for drug human oral bioavailability. J Med Chem. 2000;43:2575-2585.
118. Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm Res. 2000;17:639-644.
119. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res. 1997;14:568-571.